![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests
AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests
Read moreWed, 10th Aug 2016 09:28
AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests
Read more(Sharecast News) - Avacta Group has suspended sales of its antigen lateral flow tests, causing the AIM-listed firm's share price to plummet.
Read moreAvacta shares drop as Covid tests show reduced sensitivity to Omicron
Read moreLONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures
Read moreAIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins
Read moreAvacta shares up as flow tests receive CE mark for self-test use
Read moreAvacta confirms lateral flow tests can detect Omicron variant
Read more(Sharecast News) - Aim-listed Avacta said on Wednesday that its AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.
Read moreIN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Monday that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for its chemotherapy drug 'AVA6000'.
Read moreAvacta and Novacyt await UK regulatory approval for Covid-19 tests
Read more(Sharecast News) - Avacta said on Tuesday that it has suspended sales of its AffiDX Covid latest flow rapid antigen tests in the UK while it awaits new approval.
Read moreAvacta hails "transformative" first half despite widening loss
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group reported cash and short-term deposits of £37m at the end of its first half on Thursday, down from £54.5m a year ago and £47.9m at the start of the period.
Read moreAvacta sees pre-clinical development milestone in LG Chem partnership
Read more